nach oben

Erschienen in:

12.01.2016 | Original Article

Circulating serum levels of angiopoietin-1 and angiopoietin-2 in nasopharynx and larynx carcinoma patients

verfasst von: Murat Emin Güveli, Derya Duranyildiz, Ahmet Karadeniz, Elif Bilgin, Murat Serilmez, Hilal Oguz Soydinc, Vildan Yasasever

Erschienen in: Tumor Biology | Ausgabe 7/2016

Einloggen, um Zugang zu erhalten

Abstract

We aimed to determine the serum levels of angiogenic factors, namely angiopoietins, in nasopharyngeal and laryngeal carcinoma patients. We also aimed to seek the relation of these molecules with tumor grade and their utility as diagnostic biomarkers. We evaluated angiopoietin 1 and 2 levels innasopharynx and larynx cancer patients before treatment. Angiopoietin 2 levels were significantly elevated in larynx carcinoma patients and tended to be elevated in nasopharynx cancer patients compared with healthy controls. However, angiopoietin 1 levels were similar in cancer patients and controls. Angiopoietin 1 levels were significantly higher in nasopharyngeal cancer patients with advanced stages compared to earlier stages. On the other hand, angiopoietin 2 levels were similar in advanced and earlier stage cancer patients.

Carla C, Daris F, Cecilia B, Francesca B, Francesca C, Paolo F. Angiogenesis in head and neck cancer: a review of the literature. J Oncol. 2012;2012:358472.CrossRefPubMed

Tas F, Duranyildiz D, Oguz H, Camlica H, Yasasever V, Topuz E. Circulating levels of vascular endothelial growth factor (VEGF), matrix metalloproteinase-3 (MMP-3), and BCL-2 in malignant melanoma. Med Oncol. 2008;25:431–6.CrossRefPubMed

Demasi AP, Silva CA, Silva AD, Furuse C, Soares AB, Altemani A, et al. Expression of the vascular endothelial growth factor and angiopoietins in mucoepidermoid carcinoma of salivary gland. Head Neck Pathol. 2012;6:10–5.CrossRefPubMed

Melen-Mucha G, Niedziela A, Mucha S, Motylewska E, Lawnicka H, Komorowski J, et al. Elevated peripheral blood plasma concentrations of tie-2 and angiopoietin 2 in patients with neuroendocrine tumors. Int J Mol Sci. 2012;13:1444–60.CrossRefPubMedPubMedCentral

Huang H, Bhat A, Woodnutt G, Lappe R. Targeting the ANGPT-TIE2 pathway in malignancy. Nat Rev Cancer. 2010;10:575–85.CrossRefPubMed

Bessa V, Loukides S, Hillas G, Delimpoura V, Simoes D, Kontogianni K, et al. Levels of angiopoietins 1 and 2 in induced sputum supernatant in patients with COPD. Cytokine. 2012;58:455–60.CrossRefPubMed

Gardizi M, Kurschat C, Riese A, Hahn M, Krieg T, Mauch C, et al. A decreased ratio between serum levels of the antagonistic angiopoietins 1 and 2 indicates tumour progression of malignant melanoma. Arch Dermatol Res. 2012;304:397–400.CrossRefPubMed

Karatzanis AD, Koudounarakis E, Papadakis I, Velegrakis G. Molecular pathways of lymphangiogenesis and lymph node metastasis in head and neck cancer. Eur Arch Otorhinolaryngol. 2012;269:731–7.CrossRefPubMed

Volkova E, Willis JA, Wells JE, Robinson BA, Dachs GU, Currie MJ. Association of angiopoietin-2, C-reactive protein and markers of obesity and insulin resistance with survival outcome in colorectal cancer. Br J Cancer. 2011;104:51–9.CrossRefPubMed

10.

Wieloch M, Swiatkowska M, Libiszewski M, Hedayati M, Drozda R, Kolomecki K. Assessment of the selected, late phase of angiogenesis factors’ concentration in colorectal cancer patients. Pol Merkur Lekarski. 2009;27:466–9.PubMed

11.

Sallinen H, Heikura T, Laidinen S, Kosma VM, Heinonen S, Yla-Herttuala S, et al. Preoperative angiopoietin-2 serum levels: a marker of malignant potential in ovarian neoplasms and poor prognosis in epithelial ovarian cancer. Int J Gynecol Cancer. 2010;20:1498–505.PubMed

12.

Yuan HT, Khankin EV, Karumanchi SA, Parikh SM. Angiopoietin 2 is a partial agonist/antagonist of Tie2 signaling in the endothelium. Mol Cell Biol. 2009;29:2011–22.CrossRefPubMedPubMedCentral

13.

Hu B, Cheng SY. Angiopoietin-2: development of inhibitors for cancer therapy. Curr Oncol Rep. 2009;11:111–6.CrossRefPubMedPubMedCentral

14.

Ribatti D, Vacca A, Presta M. The discovery of angiogenic factors: a historical review. Gen Pharmacol. 2000;35:227–31.CrossRefPubMed

15.

Chien CY, Su CY, Chuang HC, Fang FM, Huang HY, Chen CM, et al. Angiopoietin-1 and -2 expression in recurrent squamous cell carcinoma of the oral cavity. J Surg Oncol. 2008;97:273–7.CrossRefPubMed

16.

Mitsutake N, Namba H, Takahara K, Ishigaki K, Ishigaki J, Ayabe H, et al. Tie-2 and angiopoietin-1 expression in human thyroid tumors. Thyroid. 2002;12:95–9.CrossRefPubMed

17.

Nagata J, Kijima H, Hatanaka H, Tokunaga T, Kamochi J, Abe Y, et al. Angiopoietin-1 and vascular endothelial growth factor expression in human esophageal cancer. Int J Mol Med. 2002;10:423–6.PubMed

18.

Xu G, Lou W, Sun Z, Zhang P. Expression of angiopoietin-1, 2 and its relationship with angiogenesis in laryngeal squamous cell carcinoma. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2008;22:772–6.PubMed

19.

Li C, Feng HC, Chen JC, Song YF. Expression and significance of angiopoietin-1 and angiopoietin-2 in oral squamous cell carcinoma. Ai Zheng. 2005;24:1388–93.PubMed

20.

Li C, Zhang B, Wang ZH, Chen JC, Li B, Wang SX, et al. Significance of a reversal expression of the angiopoietin-1 and 2 in oral squamous cell carcinoma. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2009;44:412–8.PubMed

Titel: Circulating serum levels of angiopoietin-1 and angiopoietin-2 in nasopharynx and larynx carcinoma patients
verfasst von: Murat Emin Güveli
Derya Duranyildiz
Ahmet Karadeniz
Elif Bilgin
Murat Serilmez
Hilal Oguz Soydinc
Vildan Yasasever
Publikationsdatum: 12.01.2016
Verlag: Springer Netherlands
Erschienen in: Tumor Biology / Ausgabe 7/2016
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-015-4777-0

Springer Medizin

Circulating serum levels of angiopoietin-1 and angiopoietin-2 in nasopharynx and larynx carcinoma patients

Abstract

Neu im Fachgebiet Onkologie

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

Viel pflanzliche Nahrung, seltener Prostata-Ca.-Progression

Alter verschlechtert Prognose bei Endometriumkarzinom

Darf man die Behandlung eines Neonazis ablehnen?

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2016

PIK3CA and PIK3CB silencing by RNAi reverse MDR and inhibit tumorigenic properties in human colorectal carcinoma

Long non-coding RNA tumor suppressor candidate 7 functions as a tumor suppressor and inhibits proliferation in osteosarcoma

Elevated STMN1 promotes tumor growth and invasion in endometrial carcinoma

B7-H3 increases thymidylate synthase expression via the PI3k-Akt pathway

Caveolin-1 affects tumor drug resistance in esophageal squamous cell carcinoma by regulating expressions of P-gp and MRP1

Elevated growth differentiation factor 15 expression predicts poor prognosis in epithelial ovarian cancer patients

Neu im Fachgebiet Onkologie

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

Viel pflanzliche Nahrung, seltener Prostata-Ca.-Progression

Alter verschlechtert Prognose bei Endometriumkarzinom

Darf man die Behandlung eines Neonazis ablehnen?

Update Onkologie